Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.’s Net Profit Dropped 68.8% in First Three Quarters of 2022

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (上海复旦张江生物医药股份有限公司) (688505.SH) reported a net profit of 36.7 million yuan in the first three quarters of 2022, down 68.8% year-on-year.

Meanwhile, the company posted 716.3 million yuan in revenue, up 2.6% year-on-year.

At the end of the reporting period, it had 2.9 billion yuan in total assets and 695.6 million yuan in total liabilities, with a liability-to-asset ratio of 23.9%.